Background: Cytokine treatment with Interferon-alpha (IFN-α) represents a clinical model of immune associated depression, but it remains unclear if it is of the same entity as major depressive disorder (MDD). The study focuses on possible gender differences in IFN-α induced depression and effects of a pre-emptive antidepressant treatment.
Methods: Data from 181 patients with chronic hepatitis C infection (cHC) without history of mental illnesses undergoing treatment with IFN-α 2a and ribavirin were re-analyzed for gender effects. Patients with a pre-emptive antidepressant therapy with Escitalopram (n = 90, verum group) to prevent IFN-induced depression were compared to patients who received placebo (n = 91). Depressive symptoms before and during HCV-treatment were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS), Beck's Depression Inventory (BDI) and the Hamilton Anxiety Rating Scale.
Results: We found significant differences regarding the incidence and severity of depressive symptoms between men and women for patients without antidepressant pre-treatment (placebo group). Significantly more women without pre-emptive antidepressant therapy suffered from clinically relevant depression (MADRS values ≥ 13, p = 0.041) and self-rated depressive symptoms (BDI ≥ 17, p = 0.024). Antidepressant pre-treatment showed comparable effects regarding the reduction of incidence and severity of depression in both women and men.
Conclusions: Compared to MDD, IFN-alpha-induced depression in patients with cHC is also characterized by gender differences with an increased risk for women but no gender difference regarding the effects of an antidepressant pre-treatment is found. Our data strengthens the hypothesis that Interferon-induced depression serves as a clinical model for immune related depressive disorders.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2021.05.087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis.
Pediatr Pulmonol
January 2025
Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Introduction: Depression and anxiety are common in persons with cystic fibrosis (PwCF). Genetic polymorphisms in CYP2C19 and CYP2D6 are well-established predictors of selective serotonin reuptake inhibitors (SSRIs) treatment failure yet have not been studied specifically in PwCF. The purpose of this study was to determine the rate of SSRI failure in PwCF and to identify factors that predict treatment failure.
View Article and Find Full Text PDFFrequencies of and gene variants in a German inpatient sample with mood and anxiety disorders.
World J Biol Psychiatry
April 2024
Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Würzburg, Germany.
Article Synopsis
- The study focuses on how certain gene variants (CYP2D6 and CYP2C19) influence the effectiveness of antidepressants in psychiatric patients.
- Researchers analyzed genetic data from 154 German psychiatric inpatients, finding high variability in how these patients metabolize medication.
- A significant 80% of patients had actionable pharmacogenetic (PGx) variants, suggesting the need for personalized dosing guidelines based on genetic testing to improve treatment outcomes.
The pharmacogenomic landscape of an Indigenous Australian population.
Front Pharmacol
May 2023
Centre for Genomics and Personalised Health, Queensland University of Technology, Brisbane, QLD, Australia.
Article Synopsis
- Population genomic studies on Indigenous peoples are scarce, comprising less than 0.5% of genetic database participants, which hinders access to personalized medicine for these communities.
- A pharmacogenomic study on nearly 500 individuals from the Tiwi population used whole genome sequencing and found that all participants carried at least one actionable genotype, with 77% having three or more clinically significant variants.
- Significant findings included a notably high frequency of impaired metabolism for various important pharmacogenes in the Tiwi population, which may affect the treatment and safety of several common medications, highlighting the need for tailored healthcare approaches.
[A DNA medication pass for everyone?].
Ned Tijdschr Geneeskd
April 2023
Radboudumc, afd. Farmacologie-Toxicologie, Nijmegen.
Pharmacogenetics holds the promise of personalized medicine, resulting in higher effectiveness and fewer adverse effects. Yet, the clinical benefit of a pre-emptive pharmacogenetic test has not been demonstrated rigorously. Recently an open-label real-world implementation study has been published, in which patients were randomized to either genotype-informed treatment (based on a 12-gene pharmacogenetic panel) or standard treatment.
View Article and Find Full Text PDFChronic postsurgical pain in children and young adults with cancer and choice of regional anesthesia for amputation and limb-sparing surgery.
Cancer Rep (Hoboken)
February 2023
St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Article Synopsis
- Patients undergoing limb amputation or limb-sparing surgeries face a similar risk of chronic post-surgical neuropathic pain (CPSP/NP), prompting the need for effective pain management strategies.
- This study reviewed data from 2009 to 2019 to assess the incidence and duration of CPSP/NP and the effectiveness of regional anesthesia techniques (epidurals vs. peripheral nerve blocks).
- Results indicated that limb-sparing surgeries with epidurals led to significantly better pain relief compared to limb amputations, and peripheral nerve blocks had 2.5 times higher odds of inducing CPSP/NP compared to epidurals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!